3',5'-dichloro-2'-hydroxy-4-methoxy-trans-chalcone | 62069-84-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 3',5'-dichloro-2'-hydroxy-4-methoxy-trans-chalcone
• 英文别名: 3',5'-Dichlor-2'-hydroxy-4-methoxy-trans-chalkon；1-(3,5-dichloro-2-hydroxy-phenyl)-3-(4-methoxy-phenyl)-propenone；3',5'-Dichloro-2'-hydroxy-4-methoxychalcone；(E)-1-(3,5-dichloro-2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
• CAS: 62069-84-5
• 化学式: C₁₆H₁₂Cl₂O₃
• 分子量: 323.175
• InChiKey: GTHYQSNCONPEFQ-QPJJXVBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3',5'-dichloro-2'-hydroxy-4-methoxy-trans-chalcone 在 碘 作用下， 以 二甲基亚砜 为溶剂， 以64%的产率得到6,8-dichloro-2-(4-methoxyphenyl)-4H-chromen-4-one
  参考文献：
  名称：

  Sawant; Gill; Nirwan, Indian Journal of Heterocyclic Chemistry, 2012, vol. 22, # 1, p. 61 - 66

  摘要：

  DOI：
• 作为产物：
  描述：

  3',5'-二氯-2'-羟基苯乙酮 、 4-甲氧基苯甲醛 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 以57%的产率得到3',5'-dichloro-2'-hydroxy-4-methoxy-trans-chalcone
  参考文献：
  名称：

  CDK inhibitors having flavone structure

  摘要：

  本发明涉及一种新的黄酮衍生物，其药用可接受的盐、水合物、溶剂合物和异构体，可用作对 Cyclin Dependent Kinase (CDK) 的抑制剂，以及其制备方法和包含该化合物作为活性成分的抗癌剂或治疗神经退行性疾病的药物组合物。

  公开号：

  US06500846B1

文献信息

• CDK inhibitors having flavone structure
  申请人：LG Chemical, Ltd.

  公开号：US06500846B1

  公开（公告）日：2002-12-31

  The present invention relates to a novel flavone derivative, pharmaceutically acceptable salt, hydrate, solvate and isomer thereof which is useful as an inhibitor against Cyclin Dependent Kinase (CDK), a process for preparation thereof, and a composition of anti-cancer agent or agent for treating neurodegenerative disease comprising this compound as an active ingredient.

  本发明涉及一种新的黄酮衍生物，其药用可接受的盐、水合物、溶剂合物和异构体，可用作对 Cyclin Dependent Kinase (CDK) 的抑制剂，以及其制备方法和包含该化合物作为活性成分的抗癌剂或治疗神经退行性疾病的药物组合物。
• Compounds exhibiting efflux inhibitor activity and composition and uses thereof
  申请人：Wempe Fitzpatrick Michael

  公开号：US20070254859A1

  公开（公告）日：2007-11-01

  At least one compound chosen from compounds of Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each of R 2 , R 3 , R 4 and R 5 is independently chosen from —H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z′ is chosen from —O—, —N—, —NO—, —NR 4 —, —S—, —SO— and —SO 2 —, wherein R 4 is defined as above; each of X, X′, Y and Z is independently chosen from —CR 4 R 5 —, —NH—, —NR 4 —, —NO—, —O—, —NOR 4 —, —S—, —SO—, —SO 2 —, wherein R 4 and R 5 are defined as above; R 1 is chosen from a tocopherol, a steroid and a flavonoid; and R 6 is chosen from any R 1 , alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.
• US6500846B1
  申请人：——

  公开号：US6500846B1

  公开（公告）日：2002-12-31
• [EN] COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE INHIBITRICE DE L'ECOULEMENT, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
  申请人：EASTMAN CHEM CO

  公开号：WO2007115181A9

  公开（公告）日：2008-04-03

  [EN] At least one compound chosen from compounds of Formula 1: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each Of R₂, R₃, R₄ and R₅ is independently chosen from -H, alkyl, substituted aikyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z' is chosen from -O-, -N-, -NO-, - NR₄-, -S-, -SO- and -SO₂-, wherein R₄ is defined as above; each of X, X', Y and Z is independently chosen from -CR₄R₅-, -NH-, -NR₄-, -NO-. -O-, -NOR₄-, -S-, -SO-, -SO₂-, wherein R₄ and R₅ are defined as above; R₁ is chosen from a tocopherol, a steroid and a flavonoid; and R₆, is chosen from any R₁, alkyl. substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.
  [FR] La présente invention concerne au moins un composé choisi parmi les composés de formule 1 : un sel ou un ester pharmaceutiquement acceptable de celui-ci, un solvate de celui-ci, un chélate de celui-ci, un complexe non covalent de celui-ci, un promédicament de celui-ci et des mélanges de ces derniers, n étant un nombre de 1 à 900, les unités individuelles pouvant être identiques ou différentes, W étant choisi parmi l'alkyle, l'alkyle substitué, le cycloalkyle, le cycloalkyle substitué, l'aryle, l'aryle substitué, l'aralkyle et l'aralkyle substitué, R₂, R₃, R₄ et R₅ étant chacun indépendamment choisi parmi -H, alkyle, alkyle substitué, cycloalkyle, cycloalkyle substitué, aryle, aryle substitué, aralkyle et aralkyle substitué, Z' étant choisi parmi -O-, -N-, -NO-, - NR₄-, -S-, -SO- et -SO₂-, R₄ étant tel que défini ci-dessus, X, X', Y et Z étant chacun indépendamment choisi parmi -CR₄R₅-, -NH-, -NR₄-, -NO-, -O-, -NOR₄-, -S-, -SO-, -SO₂-, R₄ et R₅ étant tels que définis ci-dessus, R₁ étant choisi parmi un tocophérol, un stéroïde et un anthoxanthine, et R₆ étant choisi parmi R₁, alkyle, alkyle substitué, cycloalkyle, cycloalkyle substitué, aryle, aryle substitué, aralkyle et aralkyle substitué.
• [EN] ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF<br/>[FR] CO-LIGANDS DES RÉCEPTEURS DES OESTROGÈNES ALPHA ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV CALIFORNIA

  公开号：WO2017132135A1

  公开（公告）日：2017-08-03

  Provided herein is a coligand for the estrogen receptor (ER) α subunit, and methods of use thereof in treating conditions associated with ER signaling in an individual. The present ERα coligand may be a cell type-selective, allosteric modulator of ERα signaling. The ERα coligand, when administered to an individual, may modulate ER agonist-dependent signaling in a tissue-selective manner.